Partnership aims to make insulin more affordable April 14, 2017By Tracey WalkerCVS, Novo Nordisk launch a prescription savings program to help patients afford essential medications. Nine ways to help diabetic patients comply April 09, 2017By Aine CrytsGetting diabetic patients to adhere to medication and dietary changes can be difficult. Here are some tips from experts. New therapies show promise in treating diabetesNew updates in insulin products, as well as non-pharma therapies are on the horizon for diabetes. Insulin makers accused of price collusion November 07, 2016By Christine BlankU.S. congressmen last week asked the Department of Justice and the Federal Trade Commission to investigate three insulin makers for price collusion—the latest in concerns over insulin prices. Importance of adherence and follow-up in patients with diabetic retinopathyA 37-year-old male came to my office for the first time in 2014 for a diabetes eye examination at the insistence of his primary-care provider (PCP). Remicade will now have a biosimilar August 24, 2016By Tracey WalkerExpert: Expectations are high that biosimilars can control overall biologic cost growth. Biosimilar drugs appear comparable to brand-name counterparts August 08, 2016By Tracey WalkerSystematic review provides comprehensive first look at TNF-alpha biosimilar treatments. Overtreating glucose levels can take a toll on diabetes patientsMayo Clinic researchers found that beyond overtesting, focus on HbA1C levels can lead to serious harms for patients, especially as more diabetes drugs are needed to keep HbA1C within desired targets. Diabetes drug Tresiba to make billions February 01, 2016By Christine BlankTresiba, the long-acting insulin that just came on the market in January, stands to net Novo Nordisk billions of dollars. High-dose insulin pen hits market January 26, 2016By Christine BlankEli Lilly & Company finally releases a high-dose insulin pen, which will help cut down on medication errors associated with the U-100 Humulin insulin pens.